Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges in the Oral Administration of Gastro-Resistant Formulations: The Role of Vehicles and Bottled Waters.

Pharmaceutics·2026
Same author

Evaluation of the Applicability of a 3D-Printed Inert Minitablet Core as a Carrier for Modified-Release Drug Delivery System.

Pharmaceutics·2026
Same author

Hybrid Nanofibers for Multimodal Accelerated Wound Healing.

Advanced healthcare materials·2026
Same author

Advances in β-Galactosidase Research: A Systematic Review from Molecular Mechanisms to Enzyme Delivery Systems.

Pharmaceutics·2025
Same author

Artificial intelligence-aided endoscopic in-line particle size analysis during the pellet layering process.

Journal of pharmaceutical analysis·2025
Same author

Microenvironmental pH-Modulated Dissolution of Albendazole Layered on Tartaric Acid Starter Pellet Cores.

Pharmaceutics·2025

Related Experiment Video

Updated: Jul 14, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

[Importance and pharmaceutical technological considerations of neutral pellets].

Nikolett Kállai, István Antal

    Acta Pharmaceutica Hungarica
    |June 20, 2007
    PubMed
    Summary

    Neutral pellets are increasingly used as starting excipients in pharmaceutical manufacturing, offering a simpler alternative to pellet agglomeration. They ensure content uniformity, especially for low-dose drugs, and are useful for modified-release and orodispersible tablets.

    More Related Videos

    Forming Micro-and Nano-Plastics from Agricultural Plastic Films for Employment in Fundamental Research Studies
    08:21

    Forming Micro-and Nano-Plastics from Agricultural Plastic Films for Employment in Fundamental Research Studies

    Published on: July 27, 2022

    Disposable Dosators Intended for Dry Powder Delivery to Mice
    04:59

    Disposable Dosators Intended for Dry Powder Delivery to Mice

    Published on: August 18, 2023

    Related Experiment Videos

    Last Updated: Jul 14, 2026

    PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
    12:48

    PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

    Published on: December 27, 2013

    Forming Micro-and Nano-Plastics from Agricultural Plastic Films for Employment in Fundamental Research Studies
    08:21

    Forming Micro-and Nano-Plastics from Agricultural Plastic Films for Employment in Fundamental Research Studies

    Published on: July 27, 2022

    Disposable Dosators Intended for Dry Powder Delivery to Mice
    04:59

    Disposable Dosators Intended for Dry Powder Delivery to Mice

    Published on: August 18, 2023

    Area of Science:

    • Pharmaceutical Sciences
    • Materials Science

    Context:

    • Growing interest in neutral pellets as pharmaceutical excipients.
    • Pellets offer a simpler manufacturing technology compared to agglomeration.

    Purpose:

    • To explore the application of neutral pellets in pharmaceutical manufacturing.
    • To highlight benefits for low-dose drugs and content uniformity.

    Summary:

    • Neutral pellets are viable starting excipients for pharmaceutical pellet production.
    • They provide a straightforward manufacturing approach.
    • Benefits include enhanced content uniformity for low-dose medications.

    Impact:

    • Facilitates development of orodispersible tablets.
    • Enables preparation of modified-release drug formulations.
    • Improves manufacturing efficiency and drug product quality.